Determination of whether HIPEC is beneficial in patients with synchronous peritoneal and liver metastases from colorectal cancer (Review)

  • Authors:
    • Nicolae Bacalbasa
    • Irina Balescu
    • Dragos Cretoiu
    • Ioana Halmaciu
    • Mihai Dimitriu
    • Bogdan Socea
    • Camelia Diaconu
    • Laura Iliescu
    • Cornel Savu
    • Carmen Savu
    • Alexandru Filipescu
    • Claudia Stoica
    • Ovidiu Stiru
  • View Affiliations

  • Published online on: September 7, 2021     https://doi.org/10.3892/etm.2021.10702
  • Article Number: 1267
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Peritoneal carcinomatosis, as well as the presence of liver metastases from colorectal cancer, has been long considered as the sign of a systemic disease, transforming the patient into a candidate for palliation and best supportive care. However, in recent decades, progress in the field of medical and surgical oncology has allowed scientists worldwide to produce curative therapeutic strategies for these cases such as hyperthermic intraperitoneal chemotherapy (HIPEC) or extended liver resection. In addition, the association of these two therapies has also been performed with encouraging results. The aim of the current study was to review articles published thus far in regard to the association of these two therapeutic strategies, in order to identify which cases can benefit the most, which is the most efficient agent or combination of agents, and whether these types of therapy should be performed as monotherapy or as a two‑stage procedure.
View References

Related Articles

Journal Cover

November-2021
Volume 22 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bacalbasa N, Balescu I, Cretoiu D, Halmaciu I, Dimitriu M, Socea B, Diaconu C, Iliescu L, Savu C, Savu C, Savu C, et al: Determination of whether HIPEC is beneficial in patients with synchronous peritoneal and liver metastases from colorectal cancer (Review). Exp Ther Med 22: 1267, 2021
APA
Bacalbasa, N., Balescu, I., Cretoiu, D., Halmaciu, I., Dimitriu, M., Socea, B. ... Stiru, O. (2021). Determination of whether HIPEC is beneficial in patients with synchronous peritoneal and liver metastases from colorectal cancer (Review). Experimental and Therapeutic Medicine, 22, 1267. https://doi.org/10.3892/etm.2021.10702
MLA
Bacalbasa, N., Balescu, I., Cretoiu, D., Halmaciu, I., Dimitriu, M., Socea, B., Diaconu, C., Iliescu, L., Savu, C., Savu, C., Filipescu, A., Stoica, C., Stiru, O."Determination of whether HIPEC is beneficial in patients with synchronous peritoneal and liver metastases from colorectal cancer (Review)". Experimental and Therapeutic Medicine 22.5 (2021): 1267.
Chicago
Bacalbasa, N., Balescu, I., Cretoiu, D., Halmaciu, I., Dimitriu, M., Socea, B., Diaconu, C., Iliescu, L., Savu, C., Savu, C., Filipescu, A., Stoica, C., Stiru, O."Determination of whether HIPEC is beneficial in patients with synchronous peritoneal and liver metastases from colorectal cancer (Review)". Experimental and Therapeutic Medicine 22, no. 5 (2021): 1267. https://doi.org/10.3892/etm.2021.10702